GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Keymed Biosciences Inc (HKSE:02162) » Definitions » Gross Profit

Keymed Biosciences (HKSE:02162) Gross Profit : HK$347.0 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Keymed Biosciences Gross Profit?

Keymed Biosciences's gross profit for the six months ended in Dec. 2023 was HK$5.6 Mil. Keymed Biosciences's gross profit for the trailing twelve months (TTM) ended in Dec. 2023 was HK$347.0 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Keymed Biosciences's gross profit for the six months ended in Dec. 2023 was HK$5.6 Mil. Keymed Biosciences's Revenue for the six months ended in Dec. 2023 was HK$29.5 Mil. Therefore, Keymed Biosciences's Gross Margin % for the quarter that ended in Dec. 2023 was 18.95%.

Keymed Biosciences had a gross margin of 18.95% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage

During the past 5 years, the highest Gross Margin % of Keymed Biosciences was 97.42%. The lowest was 84.40%. And the median was 89.59%.


Keymed Biosciences Gross Profit Historical Data

The historical data trend for Keymed Biosciences's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Keymed Biosciences Gross Profit Chart

Keymed Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
- - 113.96 108.86 346.97

Keymed Biosciences Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Gross Profit Get a 7-Day Free Trial Premium Member Only 113.96 114.25 0.02 341.38 5.59

Competitive Comparison of Keymed Biosciences's Gross Profit

For the Biotechnology subindustry, Keymed Biosciences's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Keymed Biosciences's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Keymed Biosciences's Gross Profit distribution charts can be found below:

* The bar in red indicates where Keymed Biosciences's Gross Profit falls into.



Keymed Biosciences Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Keymed Biosciences's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=387.302 - 40.337
=347.0

Keymed Biosciences's Gross Profit for the quarter that ended in Dec. 2023 is calculated as

Gross Profit (Q: Dec. 2023 )=Revenue - Cost of Goods Sold
=29.5 - 23.911
=5.6

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$347.0 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Keymed Biosciences's Gross Margin % for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=(Revenue - Cost of Goods Sold) / Revenue
=5.6 / 29.5
=18.95 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Keymed Biosciences  (HKSE:02162) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Keymed Biosciences had a gross margin of 18.95% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage


Keymed Biosciences Gross Profit Related Terms

Thank you for viewing the detailed overview of Keymed Biosciences's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Keymed Biosciences (HKSE:02162) Business Description

Traded in Other Exchanges
Address
No. 18 BioTown Middle Road, Building D2, Tianfu International BioTown, Chengdu, Sichuan, CHN, 610219
Keymed Biosciences Inc is a biotechnology company with multiple clinical-stage assets. The company is focused on the in-house discovery and development of innovative biological therapies that address large underserved medical needs in the autoimmune and oncology therapeutic areas. The Group is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment. Geographically, it operates in Hong Kong & Mainland China, out of which the majority is from Mainland China.
Executives
Chen Bo 2201 Interest of corporation controlled by you
Eagle Hero Management Limited 2101 Beneficial owner
Trident Trust Company (hk) Limited 2301 Trustee
Moonshot Holdings Limited 2101 Beneficial owner
Hh Kny Holdings Limited
Hillhouse Investment Management, Ltd.
Boyu Capital Group Holdings Ltd
Xyxy Holdings Ltd.
Tong Xiaomeng

Keymed Biosciences (HKSE:02162) Headlines

No Headlines